A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660).
Johnson, C.N., Ahn, J.S., Buck, I.M., Chiarparin, E., Day, J.E.H., Hopkins, A., Howard, S., Lewis, E.J., Martins, V., Millemaggi, A., Munck, J.M., Page, L.W., Peakman, T., Reader, M., Rich, S.J., Saxty, G., Smyth, T., Thompson, N.T., Ward, G.A., Williams, P.A., Wilsher, N.E., Chessari, G.(2018) J Med Chem 61: 7314-7329
- PubMed: 30091600 
- DOI: https://doi.org/10.1021/acs.jmedchem.8b00900
- Primary Citation of Related Structures:  
6H6Q, 6H6R - PubMed Abstract: 
Inhibitor of apoptosis proteins (IAPs) are promising anticancer targets, given their roles in the evasion of apoptosis. Several peptidomimetic IAP antagonists, with inherent selectivity for cellular IAP (cIAP) over X-linked IAP (XIAP), have been tested in the clinic ...